Type 1 Diabetes (3) Flashcards
Organ specific autoimmunity - Rogue immune cells target the pancreatic beta cells
From thymus to beta cell destruction: T1D pathogenesis
Thymus
>Developing T cells undergo selection
>positive selection to progress further and enter the periphery, or negative selection because they react to self-antigens and should be deleted (central tolerance)
>Those at risk of developing T1D have T cells that are self-reactive to beta cell antigens (failure of negative selection)
> organ specific autoimmune disease
represents a failure of self from non-self discrimination (basically a fundamental task of the immune system)
> Pancreatic lymph node
In the periphery, these naive t cells become activated, presumably in the draining lymph node or in the pancreatic islets themselves
due to the high conc of beta cell antigens present in both these places presented by the APCs that picked them up in the beta cells and moved back to the draining lymph nodes
activate the naive t cells that have escaped the thymus and these self-reactive t cells go on to infiltrate the islets and mediate the destruction of beta cells, resulting in dysregulation of glucose homeostasis
Human leukocyte antigen (HLA) locus on Chr6
T1D is an autoimmune disease involving the adaptive immune response
HLA Class II molecule:
>(alpha chain + beta chain)
>present peptides to CD4+ T cells
HLA Class I molecule:
>(alpha chain + beta-2-microglobulin chain (chr15))
>present peptides to CD8+ T cells
T cells and function
CD8+ T cells recognise peptides presented by HLA Class I molecules >cytotoxic function >directly kill the cells presenting that peptide on the HLA class I molecule
CD4+ T cells recognise peptides presented by HLA class II molecules >usually from a professional APC >will activate the APC to go on to do other functions e.g might be a B cell which goes on to produce (in the case of T1D) autoantibodies >helper function
Alleles for genes encoding MHC molecules confer the highest risk of T1D
HLA/MHC Class II (DQ locus)
>DQ2 - OR>3.6
>DQ8 - OR>11.4
>DQ2/DQ8 - OR>16.6
DQ locus consists of 2 genes
>gene that encodes the beta chain
>gene that encodes the alpha chain
>DQ2 and DQ8 is shorthand nomenclature to tell you what those alleles are for those 2 genes
HLA class II alleles confer the highest risk of type 1 diabetes
HLA DR3_DQ2, DR4-DQ8 heterozygosity confers the highest risk of T1D
OR>16.6
High risk alleles can present beta-cell antigen-derived peptides to T cells
HLA Class II molecules
>shape the T-cell repertoire during T-cell development
>Activate CD4+ T cells in the periphery
HLA locus that encodes these MHC genes is often highly associated with various autoimmune diseases
Why is the HLA class II region associated so closely with T1D (and other autoimmune diseases)?
Ongoing hypothesis:
- Beta-cell antigens may not be presented efficiently in the thymus by particular HLA molecules (e.g. DQ2 or DQ8)
- This enables the escape of low-affinity T cells from the thymus and subsequent activation by beta cell antigens that are present at high concentration in the pancreas and draining lymph nodes
(at even higher levels in the draining lymph nodes and the islets where the beta cells reside)
(if affinity is low, then the high conc of the b cell antigen at these places will help the autoantibody binding)
Genetic studies implicate non-HLA genes in T1D
Most of the alleles for these gene regions contribute relatively small risk <2.5 odds ratio
2 genes that have alleles with highest odds ratio that are non-HLA genes
>INS
>PTPN22
> > many of these genes are associated with immune function
Genetic polymorphisms for insulin associated with thymic expression and T1D risk
Key concept:
Dysregulation of negative selection generates a peripheral pool of anti-self-T cells with enhanced pathogenic potential
(displaying increased affinity and avidity)
A lot of self antigens are expressed in the thymus and presented by various cells in the medullary, so when the T cells interact with them, it sends out a signal to them to be deleted before they can get out into the periphery
> > INS = insulin
key autoantigen for human T1D
>VNTR upstream element of INS (variable number of tandem repeats)
»>Class I (26-63 repeats) = predisposing allele
»>Class III (140-210 repeats) = protective allele
> > T cell respnses
Genetic polymorphisms that affect thymic insulin expression are associated with T1D
Genetic polymorphisms that affect thymic insulin expression are associated with T1D
> > > VNTR upstream element of INS (variable number of tandem repeats)
»Class I (26-63 repeats) = predisposing allele
»Class III (140-210 repeats) = protective allele
> decreased thymic expression (of INS gene) = increased T1D risk
(T cells that recognise insulin not going to be negatively selected)
> increased thymic expression = decreased T1D risk
Reduced thymic insulin expression is predicted to:
> reduce negative selection of insulin-specific single positive thymocytes (precursor to the developed t cell that leaves and enters periphery)
> limit thymic development of beta cell-specific regulatory T cells (FOXP3+ CD4+ Tcells)
An allele for PTPN22 is associated with defective negative selection and T1D risk
Key concept:
Dysregulation of negative selection generates a peripheral pool of anti-self-T cells with enhanced pathogenic potential
(displaying increased affinity and avidity)
PTPN22 - Protein tyrosine phosphatase non-receptor 22
(is expressed in developing thymosites that become t cells in the thymus)
>genetic variant (R620W, 1858C>T mutation) associated with increased phosphatase activity and increased T1D risk
>PTPN22 is a negative regulator of T cell receptor (TCR) signalling
PTPN22 is a negative regulator of T cell receptor (TCR) signalling
Inhibiting various components of the intracellular signalling pathway, limiting transcription factors like NFAT and AP-1 binding to the DNA and causing expression of other genes
Elevated phosphatase activity (PTPN22) is predicted to:
Reduce TCR signalling and diminish apoptosis induction in beta cell-specific thymocytes
>autoreactive T cells escape to the periphery
> similar to insulin, limits thymic development of beta cell-specific regulatory T cells (FOXP3+ CD4+ T cells)
Recap on PTPN22 and INS association with defective negative selection and TD1 risk
During negative selection
>strong signal to developing thymocytes
>cause them to undergo apoptosis and die
> when you have PTPN22 allele, get increased phosphatase activity
reduce TCR signalling
reduces apoptosis induction in thymocytes that recognise B cell antigen and escape into periphery
> When you have reduced insulin expression in thymus
thymocytes who have low affintty for insulin can escape
once they get to pancreas lymph nodes, high amount of insulin makes up for that low affinity
cause immune response
PTPN22 is a negative regulator of B cell receptor (BCR) signalling
Elevated phosphatase activity is predicted to
>reduce BCR signalling and diminish apoptosis induction in autoreactive B cells
Beta-cell antigen-specific autoantibodies detected in T1D patients
If there are genetic defects affecting central tolerance, there should be evidence of autoreactive B cells and T cells in the periphery that have escaped negative selection
A number of the islet-cell specific autoantibodies (ICAs) that bind to components of the islets of Langerhans have been identified
Present in serum of people with T1D
Islet self-antigens
>insulin (produced by pancreatic beta cells)
>GAD65 (glutamic acid decarboxylase, expression not exclusive to pancreatic beta cells)
>IA-2 (tyrosine phosphatase-like protein islet antigen 2)
(not exclusive to pancreatic beta cells)
>ZnT8 (zinc transporter 8)
(zinc plays a key role in storage and secretion of insulin (hexomer), highly expressed in the endocrine but absent in exocrine pancreas. Also detected in extra-pancreatic sites)
These are antigens expressed by the beta cells
Beta cell antigens
Insulin granule
>insulin
>IA-2 (islet antigen 2)
>ZnT8 (zinc transporter 8)
Not in insulin granule
>GAD65 (glutamate decarboxylase)
Detection of islet-specific autoantibodies
Radiobinding assay
>to detect islet-specific autoantibodies (ICAs)
1) Collect serum from patient with suspected T1D
>serum containing autoantibodies
+
>radio-labelled insulin (or other beta-cell antigen)
2) Incubate and allow antigen/antibody complexes to precipitate
3) Measure radioactivity in the precipitate
>the amount of insulin specific antibody is proportional to the amount of radioactivity in the precipitate
>antibodies will start to complex and form these lattices which will precipitate in solution
Note:
Serum will contain a large collection of antibodies, with different specificities, only some will be ICAs